Valeritas Holdings’ (NASDAQ:VLRX) V-Go wearable insulin delivery device significantly lowered Type 2 diabetes (T2D) patients’ average A1C levels, compared with those using standard insulin treatment.
Valeritas’ V-GoAL trial, conducted by HealthCore, assessed 415 patients across 52 sites. In addition to obtaining greater reduction in A1C levels, T2D patients using V-Go were able to do so using approximately 24% less insulin.
“The V-GoAL clinical study demonstrates that patients with Type 2 diabetes who used V-Go as prescribed, effectively and safely lowered their A1C blood sugar levels and average insulin daily dose compared with standard treatment optimization,” John Timberlake, Valeritas’ president and CEO, said in a statement.
